Rydar Equities’s AbbVie ABBV Stock Holding History

Rydar Equities’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$129K	Buy	+474	New	+$122K	0.07%	127

Other funds holding ABBV

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Rydar Equities's ABBV Position: Q3 2026 in Review

Rydar Equities opened a new position in AbbVie (ABBV) in Q3 2026: 474 shares worth $129K. The stake represents 0.07% of the portfolio and ranks #127 among its holdings.

938 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Rydar Equities held 474 shares of AbbVie worth $129K as of Q3 2026.
AbbVie was a new Rydar Equities position in Q3 2026.
AbbVie made up 0.07% of Rydar Equities's portfolio in Q3 2026, its #127 holding.
938 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.